Bristol-Myers Squibb
BMY
BMY
2,350 hedge funds and large institutions have $80.8B invested in Bristol-Myers Squibb in 2023 Q4 according to their latest regulatory filings, with 250 funds opening new positions, 668 increasing their positions, 1,207 reducing their positions, and 239 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
11% less capital invested
Capital invested by funds: $91B → $80.8B (-$10.2B)
43% less funds holding in top 10
Funds holding in top 10: 42 → 24 (-18)
45% less repeat investments, than reductions
Existing positions increased: 668 | Existing positions reduced: 1,207
Holders
2,350
Holding in Top 10
24
Calls
$1.7B
Puts
$1.2B
Top Buyers
| 1 | +$1.14B | |
| 2 | +$184M | |
| 3 | +$165M | |
| 4 |
Primecap Management
Pasadena,
California
|
+$154M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$137M |
Top Sellers
| 1 | -$2.03B | |
| 2 | -$405M | |
| 3 | -$382M | |
| 4 |
JP Morgan Chase
New York
|
-$343M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$182M |